Follow
Tobias Bald
Tobias Bald
Group Leader, Institute for experimental Oncology, University Hospital Bonn
Verified email at ukbonn.de - Homepage
Title
Cited by
Cited by
Year
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
T Bald, T Quast, J Landsberg, M Rogava, N Glodde, D Lopez-Ramos, ...
Nature 507 (7490), 109-113, 2014
6372014
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
J Landsberg, J Kohlmeyer, M Renn, T Bald, M Rogava, M Cron, M Fatho, ...
Nature 490 (7420), 412-416, 2012
6052012
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Y Gao, F Souza-Fonseca-Guimaraes, T Bald, SS Ng, A Young, SF Ngiow, ...
Nature immunology 18 (9), 1004-1015, 2017
5282017
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing
N Gehrke, C Mertens, T Zillinger, J Wenzel, T Bald, S Zahn, T Tüting, ...
Immunity 39 (3), 482-495, 2013
4022013
The experimental power of FR900359 to study Gq-regulated biological processes
R Schrage, AL Schmitz, E Gaffal, S Annala, S Kehraus, D Wenzel, ...
Nature communications 6 (1), 10156, 2015
3312015
Immune cell–poor melanomas benefit from PD-1 blockade after targeted type I IFN activation
T Bald, J Landsberg, D Lopez-Ramos, M Renn, N Glodde, P Jansen, ...
Cancer discovery 4 (6), 674-687, 2014
2802014
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
T Bald, MF Krummel, MJ Smyth, KC Barry
Nature immunology 21 (8), 835-847, 2020
2782020
Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy
N Glodde, T Bald, D van den Boorn-Konijnenberg, K Nakamura, ...
Immunity 47 (4), 789-802. e9, 2017
2322017
Genome-wide in vivo screen identifies novel host regulators of metastatic colonization
L van der Weyden, MJ Arends, AD Campbell, T Bald, H Wardle-Jones, ...
Nature 541 (7636), 233-236, 2017
2032017
Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity
XY Li, AK Moesta, C Xiao, K Nakamura, M Casey, H Zhang, J Madore, ...
Cancer discovery 9 (12), 1754-1773, 2019
1982019
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment
S Riesenberg, A Groetchen, R Siddaway, T Bald, J Reinhardt, D Smorra, ...
Nature communications 6 (1), 8755, 2015
1922015
Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment
K Nakamura, S Kassem, A Cleynen, ML Chretien, C Guillerey, EM Putz, ...
Cancer cell 33 (4), 634-648. e5, 2018
1762018
MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy
J Reinhardt, J Landsberg, JL Schmid-Burgk, BB Ramis, T Bald, N Glodde, ...
Cancer research 77 (17), 4697-4709, 2017
1462017
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
RJ Mills, SJ Humphrey, PRJ Fortuna, M Lor, SR Foster, GA Quaife-Ryan, ...
Cell 184 (8), 2167-2182. e22, 2021
1292021
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
XY Li, I Das, A Lepletier, V Addala, T Bald, K Stannard, D Barkauskas, ...
The Journal of clinical investigation 128 (6), 2613-2625, 2018
1122018
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
SS Ng, F De Labastida Rivera, J Yan, D Corvino, I Das, P Zhang, R Kuns, ...
Nature immunology 21 (10), 1205-1218, 2020
1112020
Eomes-dependent loss of the co-activating receptor CD226 restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy
M Weulersse, A Asrir, AC Pichler, L Lemaitre, M Braun, N Carrié, ...
Immunity 53 (4), 824-839. e10, 2020
942020
CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, ...
Immunity 53 (4), 805-823. e15, 2020
872020
Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis
A Young, SF Ngiow, J Madore, J Reinhardt, J Landsberg, A Chitsazan, ...
Cancer Research 77 (17), 4684-4696, 2017
862017
Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells
IM Sektioglu, R Carretero, N Bulbuc, T Bald, T Tüting, AY Rudensky, ...
Cancer research 77 (2), 291-302, 2017
832017
The system can't perform the operation now. Try again later.
Articles 1–20